Actively Recruiting
Evaluating HSK42360-Na Tablets Plus Cetuximab With or Without Chemotherapy for BRAF V600-Mutant Metastatic Colorectal Cancer
Led by Haisco Pharmaceutical Group Co., Ltd. · Updated on 2026-08-27
180
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase III clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary effectiveness of HSK42360-Na tablets combined with cetuximab, with or without chemotherapy, in patients with BRAF V600-mutant metastatic colorectal cancer. This trial includes a dose escalation phase to find the best dose and a cohort expansion phase to assess efficacy and safety in different treatment combinations. In Phase I, participants receive escalating doses of HSK42360-Na tablets orally once, twice, or three times daily combined with cetuximab given intravenously every two weeks. After determining the recommended dose, Phase II includes three groups receiving HSK42360-Na with cetuximab alone or combined with either mFOLFOX6 or FOLFIRI chemotherapy regimens. Treatment continues until disease progression, unacceptable side effects, or withdrawal. Participants undergo tumor assessments every 6 weeks initially and every 8 weeks after 18 months, with safety follow-up 30 days after the last dose and survival follow-up every 3 months. Researchers measure dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, response rates, progression-free and overall survival, and duration of response over up to 36 months to understand treatment effects and safety.
CONDITIONS
Brief Title
HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer
Research Team
L
lin shen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here